MIRA INFORM REPORT

 

 

Report Date :

17.12.2013

 

IDENTIFICATION DETAILS

 

Name :

INTERNATIONAL PHARMA LABS (IPL)

 

 

Registered Office :

116-Zulqernain Chamber, Ganpat Road, Lahore, Punjab

 

 

Country :

Pakistan

 

 

Date of Incorporation :

August, 2005

 

 

Legal Form :

Sole Proprietorship

 

 

Line of Business :

Manufacturing of Veterinary Pharmaceutical Products

 

 

No. of Employees :

6

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 


NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

 

Source : CIA

 


company name

 

INTERNATIONAL PHARMA LABS (IPL)

 

 

GENERAL INFORMATION

 

Business Name

INTERNATIONAL PHARMA LABS (IPL)

Address

Head Office / Registered Office:

116-Zulqernain Chamber, Ganpat Road, Lahore, Punjab-Pakistan.

 

Factory Address: Raiwind road, Bhoptain Chowk, Defence road, 1 km towards Kahna, Lahore, Punjab- Pakistan

Telephone

+92-42-37323037

+92-42-37354231

Fax

+92 – 42 – 37233457

Mobile

+92 – 332 – 4446687   

 Mr. Gohar Abbas Jawa

Email

gohar-e-abbas@yahoo.com

sales@ipharmalabs.com

support@ipharmalabs.com

Website

http://www.ipharmalabs.com/

Business activities

Manufacturing of Veterinary Pharmaceutical Products

 

Registry Details

IPL is a Proprietorship concern, registration with any regulatory body is not mandatory.

 

CRO Registration Number

N/A

 

Date of Registration

 

Other registry & certification details:

Current Legal Form

Sole Proprietorship

National Tax Registration Number

Not Disclosed

Date of Registration

N/A

GST Registration Number

Not Disclosed

Date of Registration

N/A

Chamber of Commerce & Industry

The Lahore Chamber of Commerce & Industry

Date of Registration

Undetermined

ISO Certification

None

Date of Registration

N/A

Other certifications

Undetermined

Date of Registration

N/A

 

History

 

Who started

Sh. Ali Akbar Jawa

When started

August 2005

Change in management

None

Year of change

N/A

Change in legal status

None

Year of change

N/A

Change in business name

None

Year of change

N/A

 

 

PRINCIPALS (SPONSORS)

 

Name

Number of Shares

Nationality

Appointment Date (Last)

Sh. Ali Akbar Jawa

100%

Pakistani

Not Disclosed

 

 

KEY MANAGEMENT

 

Name

 

Position in organization

Qualification

Years in employment

Gohar Jawa

Manager

Not Disclosed

Not Disclosed

 

Statutory offices

 

Statutory Auditors

Not Disclosed

Legal Advisory Services

Not Disclosed

 

 

BANKERS

 

Bank name

 

Approved financing limits

Soneri Bank Ltd.

 

Depository Relation

 

 

DETAILS OF BUSINESS ACTIVITIES

 

The primary focus of the concern is manufacturing of Veterinary Medicines which is imported in different parts of the world including Asia, Europe and Russia. Some of its products include:

 

Product's Categories

·         Feed additives

·         Nutritional water soluble powders

·         Medicinal water soluble powders

·         Injectables

·         Nutritional oral liquids

·         Medicinal oral liquids

·         Miscellaneous

·         Pesticides

·         Bolus

 

Product's Type

·         Antibiotics (Non penicillins)

·         Analgesics

·         Anthelmintics

·         Anti-inflammatories

·         Antibiotics (penicillins)

·         Corticosteroides

·         Electrolytes

·         Growth stimulators

·         Hormones

·         Iron & Iron compounds

·         Minerals

·         Pesticides

·         Theileriosis

·         Trypanosomiasis

·         Vitamins

 

Purchases (Incl. Imports)

Imports from

Not Disclosed

Importing terms

Local (%)

Local buying terms

 

Sales (Incl. Exports)

Exports to

Not Disclosed

Exporting terms

Local (%)

Local selling terms

 

 

NUMBER OF EMPLOYEES

 

Nature of employment

Current Year

Previous Year

All Staff

6

6

Total

6

6

 

 

BUSINESS FACILITIES

 

Head office Address

 

Owned / Rented

Area (approx)

116-Zulqernain Chamber, Ganpat Road, Lahore, Punjab-Pakistan.

 

Details not provided.

Factory Address

 

Owned / Rented

Area (approx)

Raiwind road, Bhoptain Chowk, Defence road, 1 km towards Kahna, Lahore, Punjab- Pakistan 18000sq ft area

Details not provided

Warehouse Address

Owned / Rented

Area (approx)

None                                                                                                                    

 

 

MARKET REPUTATION

 

During the market check of the subject company we came to know that the subject company belongs to ‘Jawa Group’ which is known as leading manufacturer of pharmaceutical products and well known as profitable business in the industry.

IPL is not very well known in the market but the group is quite known in the same industry. During market check we observed that companies gave a very good response of the JAWA group but knew little about IPL. No complaints or disputes were reported during the market check.

 

 

DETAILS OF RELATED BUSINESSES

 

Business Name

City

Line of Business

Percentile of Shareholding

Wilshire Labs.(Pvt) Ltd.

LAHORE

Pharmaceutical Medicines

NOT PROVIDED

Jawa Pharma (Pvt) Ltd)

LAHORE

Pharmaceutical Medicines

NOT PROVIDED

Irza Pharma

LAHORE

Pharmaceutical Medicines

NOT PROVIDED

 

 

BUSINESS PERFORMANCE (NOT PROVIDED)

 

The Contact person decline to share financial information.

 

 

INTERVIEW & REPORTER COMMENTS

 

Contact person

Mr. Gohar Abbas Jawa

Position

Manager

Comments

We visited the said business premises, the contact person confirmed business operations but declined to provide any further information.

Analyst Observations

The company office is quite well build and suitable for this kind of business.

The contact person was very reluctant to disclose the details of the company.

He declined to disclose the financial information.

 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.10

UK Pound

1

Rs.101.27

Euro

1

Rs.85.43

 

 

INFORMATION DETAILS

 

Report Prepared by :

NNA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.